Amicus Therapeutics Inc., of Cranbury, N.J., said results from preclinical studies of its next-generation Pompe enzyme replacement therapy (ERT) were featured at WorldSymposium 2015 in Orlando, Fla., and that they support clinical development of ATB200 in combination with a chaperone.